The FDA’s shift toward organoid-based and AI-powered drug testing marks a new era in biotech. Opal Therapeutics is leading in women’s health with our uterus-in-a-dish platform—using patient-derived uterine organoids to model diseases like endometriosis and fibroids with human-relevant precision.